lactobacillus plantarum L168

Lactobacillus plantarum L168 is a specific probiotic bacterial strain of the species Lactobacillus plantarum, isolated and preserved under the accession number CGMCC No.13660. It has demonstrated multiple beneficial effects in preclinical studies, including modulation of gut microbiota composition, enhancement of immune function, and anti-inflammatory activity. Notably, it has been shown to: - Delay ovarian aging by increasing mature oocyte numbers and improving fertility in Drosophila models with kdm5 gene deficiency[1][3]. - Assist in the treatment of hepatocellular carcinoma (HCC) when used alongside sorafenib by promoting ferroptosis in cancer cells and alleviating sorafenib-induced colonic inflammation[2]. - Improve outcomes in bronchopulmonary dysplasia (BPD) animal models by reducing lung injury, enhancing lung development, improving intestinal permeability, increasing anti-inflammatory metabolites, and downregulating inflammatory pathways such as TLR4/NF-κB/CCL4[7]. The primary mechanism involves modulation of host immune responses through alteration of gut microbiota composition and suppression of pro-inflammatory signaling pathways.

Other names

植物乳杆菌L168LP-L168LP-L-168LP-L 168